Asian stock markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.4% while the Hang Seng is down 0.7%. The Shanghai Composite is trading down by 0.3%. Meanwhile, Wall Street’s major indices fell on Thursday as trade-sensitive stocks were hit by a fresh round of tariffs in the trade dispute between the United States and China.
Back home, India share markets have opened the day on a flat note. The BSE Sensex is trading up by 30 points while the NSE Nifty is trading up by 6 points. The BSE Mid Cap index opened up by 0.2% and BSE Small Cap index opened the day down by 0.1%.
The rupee is currently trading at 70.07 to the US$.
Sectoral indices have opened the day on a mixed note with power stocks and capital goods stocks witnessing maximum buying interest. While FMCG stocks and bank stocks have opened the day in the red.
In the news from the pharma sector. As per an article in a leading financial daily, Lupin has entered the prescription dermatology segment in Brazil with the launch of two products Fillerina and Recrexina in the country.
Fillerina is a high-end anti-aging technology that incorporates a deep action innovative formulation to fill wrinkles and expression lines. Recrexina, on the other hand, is a hair-growth formulation which stimulates natural hair growth in active and partially inactive follicles.
The dermatology segment is a rapidly growing portion of the Brazilian pharmaceutical market.
Valued at US$ 28 billion, Brazil is the world’s sixth largest pharmaceutical market, driven by growing public health expenditure and increasing household income.
The dermatology segment in Brazil is worth US$ 1.5 billion and growing at 10% (CAGR) is one of the fastest growing segments in the country.
Lupin Brazil clocked sales of BRL 157 million during 2017-18 making it the largest Indian company in Brazil by volume and second largest by value.
No Comments